Opioid-induced cardioprotection occurs via glycogen synthase kinase beta inhibition during reperfusion in intact rat hearts.

Abstract

Glycogen synthase kinase (GSK) inhibition produced by ischemic preconditioning has been previously shown to be regulated through phosphatidylinositol-3 kinase (PI3K). Therefore, we determined whether opioid-induced cardioprotection (OIC) occurs during reperfusion by altering GSK phosphorylation through PI3K and target of rapamycin (TOR). Furthermore, we determined if selective GSK inhibitors, SB216763(SB21) or SB415286(SB41), emulate OIC. Rats were treated with the nonselective opioid agonist, morphine (MOR, 0.3 mg/kg), the delta-selective opioid agonist BW373U86 (BW, 1 mg/kg), or the GSK inhibitors, SB21 (0.6 mg/kg) or SB41(1.0 mg/kg), either 10 minutes before ischemia or 5 minutes before reperfusion. Five minutes before opioid or SB21 treatment, some rats received either the PI3K inhibitor wortmannin (15 microg/kg) or LY294002 (0.3 mg/kg) or the TOR inhibitor rapamycin (3 microg/kg). After 30 minutes of ischemia followed by 2 hours of reperfusion, infarct size was assessed. MOR, BW, SB41, and SB21 reduced infarct size compared with vehicle when administered before ischemia (42.9+/-2.6, 40.3+/-2.3, 46.6+/-1.6, 42.2+/-1.8 versus 60.0+/-1.1%, respectively; P<0.001) and showed similar protection when administered 5 minutes before reperfusion (43.6+/-2.3, 40.2+/-2.6, 44.8+/-2.8, 39.4+/-0.8%, respectively; P<0.001). Wortmannin, LY294002, and rapamycin were found to inhibit OIC; however, they did not abrogate SB21-induced infarct size reduction. At 5 minutes of reperfusion, both MOR and BW increased P-GSKbeta at Ser9 in the ischemic zone compared with vehicle (181+/-20, 178+/-15 versus 75+/-17 DU, respectively; P<0.05), and this effect was abrogated by prior administration of wortmannin or rapamycin in MOR-treated rats. Furthermore, no differences were seen in phosphorylation of GSKalpha (Ser21 or Tyr279) or phosphorylation of GSKbeta (Tyr216). These data indicate that OIC occurs via the phosphorylation of GSKbeta at Ser9 during reperfusion.

• Authors: Eric R Gross, Anna K Hsu, Garrett J Gross
• Journal: Circulation research (Circ Res) Vol. 94 Issue 7 Pg. 960-6 (Apr 16 2004) ISSN: 1524-4571 [Electronic] United States
• PMID: 14976126 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't, Research Support, U.S. Gov't, P.H.S.)

Chemical References

• 3-(3-chloro-4-hydroxyphenylamino)-4-(4-nitrophenyl)-1H-pyrrole-2,5-dione
• Aminophenols
• Androstadienes
• Benzamides
• Cardiotonic Agents
• Chromones
• Indoles
• Maleimides
• Morpholines
• Narcotic Antagonists
• Nuclear Receptor Subfamily 1, Group F, Member 3
• Phosphoinositide-3 Kinase Inhibitors
• Piperazines
• Receptors, Opioid, delta
• Receptors, Retinoic Acid
• Receptors, Thyroid Hormone
• Rorc protein, rat
• SB 216763
• BW 373U86
• 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one
• Morphine
• Glycogen Synthase Kinase 3 beta
• Glycogen Synthase Kinase 3
• Sirolimus
• Wortmannin

Topics

• Aminophenols (pharmacology)
• Androstadienes (pharmacology)
• Animals
• Benzamides (pharmacology)
• Cardiotonic Agents (pharmacology, therapeutic use)
• Chromones (pharmacology)
• Glycogen Synthase Kinase 3 (antagonists & inhibitors, physiology)
• Glycogen Synthase Kinase 3 beta
• Indoles (pharmacology)
• Male
• Maleimides (pharmacology)
• Morphine (pharmacology)
• Morpholines (pharmacology)
• Myocardial Infarction (metabolism, pathology)
• Narcotic Antagonists (pharmacology)
• Nuclear Receptor Subfamily 1, Group F, Member 3
• Phosphatidylinositol 3-Kinases (physiology)
• Phosphoinositide-3 Kinase Inhibitors
• Piperazines (pharmacology)
• Premedication
• Rats
• Rats, Sprague-Dawley
• Receptors, Opioid, delta (drug effects)
• Receptors, Retinoic Acid (antagonists & inhibitors, physiology)
• Receptors, Thyroid Hormone (antagonists & inhibitors, physiology)
• Signal Transduction (drug effects)
• Sirolimus (pharmacology)
• Wortmannin